AHFS Drug Information®
2020, 2021, 2022, 2023, 2024 Doody's Core Titles List Selection I 5-Star Rating from Doody's Review Service
AHFS DI is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients.
Benefits that are unique to AHFS DI include:
- The only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.
- The only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization.
2025 Edition Updates
- Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
- Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
- Contemporary topics such as vaccines and treatments for mPox disease, new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
- MedWatch alerts, Standardize4Safety concentration standards for IV and oral liquid medications, REMS data, and focused updates based on FDA safety findings
+ View all updates
- Expanded content on new and emerging gene therapies
- Pharmacogenomic considerations in drug dosing and selection
- Updates to a variety of vaccine monographs including the influenza, COVID-19, pneumococcal, and RSV vaccines with the latest recommendations from the CDC Advisory Committee on Immunization Practices (ACIP)
- Expanded content on off-label uses, real world data and long-term clinical data
- New content on over 200 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 265 medications
- Oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee
ADVERTISEMENT
AHFS Clinical Drug Information App
AHFS CDI expands your access to real-time drug and safety updates by linking directly and in context to 20 additional specialty databases. Easily switch between concise, direct point-of-care, actionable drug information with AHFS DI Essentials, or the full database contents of AHFS Drug Information.
With AHFS CDI you can:
- Have constant access to all the latest updates— including drug shortages information
- Toggle between a quick summary of essentials and a comprehensive monograph
- Review compatibility matrices for patient care at the bedside
- View seamlessly incorporated FDA safety data
...includes a collection of drug monographs for virtually every single drug entity available in the U.S.Jennifer L. Colon, PharmD, MS, MBA
...access quickly and easily, the specific guidance needed to prescribe and monitor drug therapy safely and effectively.Laurence A. Goldberg